Metabolic disorders cause liver damage in people with HIV more often than viral hepatitis in lower-income countries
Better adherence to PrEP is associated with more bone loss
Injectable cabotegravir plus rilpivirine every two months maintains viral suppression for three years, but carries higher risk of treatment failure
Long COVID more common in people with HIV
Top 5 HIV treatment stories from CROI 2022
Top 5 HIV cure and vaccine stories from CROI 2022
Top 5 stories on HIV, ageing and co-morbidities from CROI 2022
Top 5 stories on HIV prevention from CROI 2022
Top 5 stories on HIV treatment and care in Africa from CROI 2022
Generic PrEP for young, at-risk MSM in the US could be cost-saving and health-enhancing
Broadly neutralising antibody treatment: is pre-existing resistance its Achilles heel?
Why did an HIV vaccine fail in the Imbokodo trial?
Lenacapavir shows continued promise for first-line treatment and highly resistant HIV
Injected PrEP: breakthrough cases could have been detected sooner
Have HIV-associated neurological disorders declined in people with HIV due to recent antiretrovirals?
Further evidence that recycling tenofovir in second-line treatment is effective
Infant weight and height lower with efavirenz than with dolutegravir in pregnancy
Virtual approaches boost HIV self-testing in India
